Blog & Resources Camargo Blog September 2nd, 2008

Shionogi to Buy Sciele Pharma

Shionogi, a Japan-based pharmaceutical company, announced yesterday (9/1/2008) that it would buy Atlanta-based Sciele Pharma for $1.42 billion – 57% premium to the current share price. Shionogi’s analysis of the purchase is here. Sciele’s business strategy relies on 505(b)(2) drug development. Sciele in-licenses products in a wide range of therapeutic categories. Products include fenofibrate (lower doses), clonidine (sustained-release) and nitroglycerin (oral spray).

Apparently, Shionogi is buying both existing products, a pipeline and, most importantly, a seasoned sales force.

It’s nice to see 505(b)(2) products going for such multiples!

Categories: 505(b)(2) Development

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights